GlaxoSmithKline Capital PLC Publication of a Prospectus (5697L)

TIDMAG99

RNS Number : 5697L

GlaxoSmithKline Capital PLC

30 April 2020

Issued: 30 April 2030, London UK - LSE Announcement

Publication of Supplementary Prospectus

The following supplementary prospectus dated 30 April 2020 to the Prospectus dated 2 August 2019 has been approved by the Financial Conduct Authority and is available for viewing:

GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GSK Capital K.K. GBP20,000,000,000 Euro Medium Term Note Programme

Copies of the supplementary prospectus and the documents incorporated by reference within it have been submitted to submitted to the UK Listing Authority's NSM submission portal via the Electronic Submission System (ESS). A copy can be viewed at:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

For further information, please contact:

GlaxoSmithKline plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

Enquiries:

BASIS ON WHICH YOU MAY ACCESS THE BASE PROSPECTUS

Please note that the information contained in the supplementary prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the base prospectus you must ascertain from the base p rospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above

 
 GlaxoSmithKline plc 
  Registered in England & Wales: 
  No. 3888792 
 
 Registered Office: 
  980 Great West Road 
  Brentford, Middlesex 
  TW8 9GS 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

PDIBLGDSCSXDGGG

(END) Dow Jones Newswires

April 30, 2020 12:51 ET (16:51 GMT)